Pelabresib not checked
Novartis · DAK539 · CPI-0610
FollowEvery change as it happens, and a Monday email
Trials
7 active
7 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days). Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.”In the company’s words, NCT04603495 on ClinicalTrials.gov
- Tested for
- Primary Myelofibrosis (PMF) (2 trials), Advanced Malignancies (2 trials), Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) and 5 more
- Main trialPhase 3
- “A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.”In the company’s words, NCT04603495 on ClinicalTrials.gov
- Other names
- DAK539 · CPI-0610
Other drugs for Primary Myelofibrosis (PMF)
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- ElriterceptTakeda · Phase 3
- Imetelstat SodiumGeron Corporation · Phase 3
Coming up4
- 9 Mar 2028Phase 1 trial completes · ClinicalTrials.gov
- 17 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2027-06-02 to 2029-12-31 · ClinicalTrials.gov NCT06401356
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 23 Aug 2023 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | |
| Phase 3Recruiting | 17 May 2028 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | |
| Phase 3Recruiting | 31 Dec 2029 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | |
| Phase 1Active, not recruiting | 23 Jul 2026 | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | |
| Phase 1Recruiting | 13 Nov 2026 | A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants | |
| Phase 1Recruiting | 9 Mar 2028 | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies | |
| Phase 1Recruiting | 28 Jun 2028 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026